On the inhibition of interferon action by inhibitors of fatty acid cyclooxygenase

Arachidonic acid regulates the binding of human interferon in human skin fibroblasts

The induction of the antiviral state in human fibroblasts by human interferon is inhibited by arachidonic acid, its analogues 5,8,11,14-eicosatetraynoic and 5,8,11-eicosatriynoic acids, as well as by sodium arachidonate. The fatty acids myristic or oleic acid and sodium palmitate do not inhibit the antiviral action of interferon. Experiments were conducted to investigate the mechanism by which arachidonic acid could inhibit the action of interferon. No correlation between cellular lipoxygenase activities and the inhibition of antiviral action of interferon was observed in the fatty acid treated cells. Likewise, the cyclooxygenase inhibitors indomethacin and oxyphenylbutazone do not inhibit the interferon-induced antiviral state. Taken together, the inhibition of interferon action by arachidonates is unlikely to be mediated by cyclooxygenase or lipoxygenase-generated intermediates, even though arachidonates are known to affect the activity of these enzymes in vitro. Measurement of interferon receptors in the fatty acid treated cells showed that arachidonic acid, sodium arachidonate and its analogues decreased the number of human type I interferon receptors available for binding, and inhibited the transcription of the interferon-induced 6-16 gene and the induction of cellular (2'-5')-oligoadenylate synthetase, suggesting the mechanism of inhibition is mediated at the level of the interferon receptor. The significance of the finding that arachidonic acid, a common fatty acid of cells and serum, can affect the antiviral action of interferon is discussed.

Effect of indomethacin, aspirin, and acetaminophen on in vitro antiviral and antiproliferative activities of recombinant human interferon-alpha 2a

The effects of indomethacin, aspirin, and acetaminophen on the antiviral and antiproliferative activities of recombinant human interferon-alpha 2a (rIFN-alpha 2a) were studied in vitro. None of the drugs inhibited the antiviral activity of rIFN-alpha 2a in human amnion FL cells against vesicular stomatitis virus, or interfered with its antiproliferative activity against acute lymphoblastic leukemia MOLT-4 cells or renal cell carcinoma NC 65 cells. Although, at high concentrations, aspirin (1 mM) or indomethacin (0.1 mM) alone inhibited the cell growth, rIFN-alpha 2a showed clear additive growth inhibition. It was concluded that neither indomethacin, aspirin, nor acetaminophen directly inhibited the antiviral and antiproliferative activities of rIFN-alpha 2a. The possible use of these three drugs to reduce the adverse effects of rIFN-alpha 2a without spoiling its profitable efficacy in clinical practice is suggested.

Interferon induction by viruses. XIV. Development of interferon inducibility and its inhibition in chick embryo cells "aged" in vitro

Studies with a number of viruses revealed a time-dependent acquisition of interferon (IFN) inducibility in primary chick embryo cells as they "aged" in vitro for 2-12 days at a confluent cell density without a medium change. The time-course for the development of IFN inducibility was established by generating and analyzing a family of dose (multiplicity)-response (IFN yield) curves, using Newcastle disease virus (NDV, strain LaSota) as the inducer. Cells produced little or no IFN for the first 4-5 days. Between 5 and 6 days the cells gradually developed the capacity to respond to NDV (and other viruses). Maximal yields of IFN were inducible by day 10. This time-dependent development of IFN inducibility was abrogated almost completely when "aging" was carried out in the presence of drugs that inhibited the synthesis of cyclic derivatives of C20 oxygenated unsaturated fatty acids, i.e., inhibitors of prostaglandin/leukotriene synthesis and the arachidonic acid cascade. Of the prostaglandin synthesis inhibitors, indomethacin was particularly effective. Cells treated on day 0 with 10 micrograms/ml of indomethacin produced 100- to 1000-fold less IFN than controls when induced on day 8. To prevent maximally the development of IFN inducibility, indomethacin must be added within the first 2 days of seeding. After about 2 days, the cells begin to escape the action of the drug. Indomethacin added at the time of induction had no effect on the yield of IFN. IFN inducibility was partially restored when indomethacin was removed during the aging process. "Aging" chick cells in low concentrations of cycloheximide (0.5 micrograms/ml) produced results comparable to incubation with indomethacin. Neither reagent had any marked effect on the rate of total protein or RNA synthesis, nor did their action prevent the induction of stress (heat shock) proteins. Cells "aged" in indomethacin were threefold less efficient in responding to the action of IFN, whereas aging in cycloheximide had no effect on IFN's action. Plaque formation on drug-treated cells was normal for viruses that were poor inducers of IFN. However, both the plaquing efficiency and plaque size of Sindbis virus (an excellent IFN inducer) were enhanced markedly on cells treated with indomethacin or low concentrations of cycloheximide during the aging process. These data implicate a family of fatty acid derivatives of arachadonic acid, including prostaglandins and leukotrienes, in the development of IFN inducibility in primary chick embryo cells "aged" in vitro.

Reversible restriction of vesicular stomatitis virus in permissive cells treated with inhibitors of prostaglandin biosynthesis

Indomethacin, a potent nonsteroidal inhibitor of prostaglandin synthetase (cyclooxygenase) reduced yields of infectious vesicular stomatitis virus in HEp-2 cells more than 99% if added to cultures at levels of 10(-3)M either before or after infection. Other permissive cell lines differed according to the treatment period and drug level required for restricting productive infections. The inhibitory effect of indomethacin was progressively reduced if infection of cells was delayed for increasing times after drug removal. Strong inhibition of viral replication also occurred in cells treated with the cyclooxygenase antagonists naproxen, phenylbutazone, and oxyphenylbutazone whereas phenacetin, which does not block cyclooxygenase function, was inactive. Enhanced viral replication occurred in indomethacin-treated HEp-2 cultures when these cells were subsequently exposed to such substances as prostaglandin E1, cyclic AMP, or insulin. Conversely, indomethacin-treated cells remained restrictive for VSV if they were subsequently exposed to metabolic inhibitors of functional DNA (actinomycin D or mitomycin C), messenger RNA synthesis (alpha-amanitin), or protein synthesis (cycloheximide) at concentrations that normally do not compromise viral replication. Pretreatment of HEp-2 cells with mitomycin C markedly shifted the dose response for indomethacin-mediated inhibition of VSV from a 90% inhibitory dose of about 10(-4)M to one of 10(-9)M or lower. These findings suggest that preexisting host factors essential for replication of VSV, although rendered nonfunctional by the drug indomethacin, can be replenished unless their synthesis is blocked by various classes of metabolic inhibitors.

Effects of procaine and oxyphenylbutazone on interferon-mediated inhibition of murine leukemia virus production

Treatment of murine NIH/MOL, C cells which are chronically infected with Moloney murine leukemia virus (MuLV), with mouse interferon (IFN), causes inhibition of extracellular MuLV production. We tested the effect of procaine, a drug that is known to expand cellular membranes and to increase their fluidity, on IFN-mediated inhibition of MuLV production. We observed that procaine did not alleviate this inhibition when IFN was present during procaine treatment. However, if IFN was removed from the culture medium before procaine treatment, the inhibition of MuLV production was partially reversed. We also observed that procaine treatment caused an increase in the amount of MuLV production by cells which had not been treated with IFN. Oxyphenylbutazone (OPB) is an inhibitor of cyclooxygenase, a key enzyme in prostaglandin biosynthesis. New synthesis of prostaglandins is thought to be needed for the antiviral actions of IFN. We observed that OPB did not prevent the antiretroviral action of IFN on NIH/MOL, C cells. OPB also failed to alleviate the IFN-mediated inhibition of replication of vesicular stomatitis virus either in NIH/MOL, C cells or in the L929 cells.